Abstract Details

Title Diagnosed and Drug-Treated Prevalence of Essential Tremor in Adult Patients: Retrospective Analyses of Two US Healthcare Claims Databases

Topic Movement Disorders

Presentation(s) S51 - Movement Disorders: Tremor, Parkinsonism, and Non-motor Symptoms (4:06 PM-4:18 PM)

Poster/Presentation
Number 004

Background ET is a chronic, heterogeneous, and progressive neurological disorder that can impact activities of daily living. Few epidemiological studies describe the prevalence of diagnosed or drug-treated ET in the US.

Objective To estimate the prevalence of diagnosed and drug-treated essential tremor (ET) in the adult population using two US healthcare claims databases.

Design/Methods A retrospective cohort study was conducted using Merative™ MarketScan^® Research Databases (MarketScan^®) and Symphony Integrated Dataverse (IDV^®) (01/01/2016–12/31/2019) to estimate the number of US adults (age ≥18 years) with ET. ET diagnosis was defined as ≥2 medical claims containing ICD-10-CM code G25.0 ≥1 and ≤365 days apart. Patients with drug-treated ET were defined as those with ≥180 days of observability following ET diagnosis who subsequently received any ET medication in 2019. Age-adjusted prevalence was used to estimate the number of US adults with diagnosed and drug-treated ET.

Results Estimated age-adjusted numbers (95% CIs) of US adults diagnosed with ET were 782,800 (770,666–795,119) and 525,115 (522,893–527,457) using MarketScan and IDV, respectively. The majority of those diagnosed with ET also received pharmacological treatment for ET. Specifically, the estimated proportions (95% CIs) of adult patients with ET who were drug-treated were 73.8% (73.1%–74.4%) and 74.8% (74.6%–75.0%), respectively. Estimated age-adjusted numbers (95% CIs) of adult patients with drug-treated ET were 588,489 (578,043–599,067) and 391,680 (389,570–393,668), respectively. Beta-blockers (64% and 61%, respectively) and anticonvulsants (53% and 61%, respectively) were the most common drug classes prescribed among those treated. The most frequently prescribed beta-blocker and anticonvulsant were propranolol (41% and 35%, respectively) and primidone (27% and 32%, respectively).

Conclusions ET affects many US adults, most of whom are treated. Many patients receive regimens not indicated as first-line for ET, suggesting the need for novel therapies indicated for this condition.

Authors/Disclosures
Junji Lin, PhD (Jazz Pharmaceuticals) PRESENTER	Ms. Lin has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Ms. Lin has stock in Jazz Pharmaceuticals.
Ragy Saad (Jazz Pharmaceuticals)	No disclosure on file
Michael Markowitz, MD	Dr. Markowitz has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Dr. Markowitz has stock in Jazz Pharmaceuticals, UCB Pharmaceuticals, J&J.
	No disclosure on file
Douglas S. Fuller (Jazz Pharmaceuticals)	Mr. Fuller has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Mr. Fuller has stock in Jazz Pharmaceuticals.
Weiyi Ni	No disclosure on file
Rajesh Pahwa, MD, FAAN (University of Kansas Medical Center)	Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbott. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie. Dr. Pahwa has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for ACADIA. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Acorda. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amneal. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Kyowa. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Supernus. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allevion. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Insightec. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jaaz. Dr. Pahwa has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neuroderm. Dr. Pahwa has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Photopharmics. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sage. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Fasikl. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genetech. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merz. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sun Biopharma. The institution of Dr. Pahwa has received research support from Abbott. The institution of Dr. Pahwa has received research support from Abbvie. The institution of Dr. Pahwa has received research support from Biogen. The institution of Dr. Pahwa has received research support from Biohaven. The institution of Dr. Pahwa has received research support from EIP. The institution of Dr. Pahwa has received research support from Amneal. The institution of Dr. Pahwa has received research support from Parkinson Foundation. The institution of Dr. Pahwa has received research support from Roche. The institution of Dr. Pahwa has received research support from Sage. The institution of Dr. Pahwa has received research support from Sun Pharma. The institution of Dr. Pahwa has received research support from Theranexus. The institution of Dr. Pahwa has received research support from Theravance. The institution of Dr. Pahwa has received research support from Voyager. The institution of Dr. Pahwa has received research support from Neuroderm. The institution of Dr. Pahwa has received research support from Annovis. The institution of Dr. Pahwa has received research support from Ask Bio. The institution of Dr. Pahwa has received research support from Blue Rock. The institution of Dr. Pahwa has received research support from Cerevance. The institution of Dr. Pahwa has received research support from Fasikl. The institution of Dr. Pahwa has received research support from Praxis. The institution of Dr. Pahwa has received research support from Scion. The institution of Dr. Pahwa has received research support from UCB.
Kelly E. Lyons, PhD (University of Kansas Medical Center)	Dr. Lyons has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Praxis. Dr. Lyons has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sage. Dr. Lyons has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Parkinson's Foundation. Dr. Lyons has a non-compensated relationship as a President with International Essential Tremor Foundation that is relevant to AAN interests or activities.
Michelle Baladi, PhD (Jazz Pharmaceuticals)	Dr. Baladi has stock in Jazz Pharmaceuticals .